| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 187.3 | 166.3 | 168.2 |
| Other income | -4.2 | 15.1 | -6.9 |
| Total income | 183.1 | 181.5 | 161.3 |
| Profit before exceptional items & tax | 16.7 | 34.7 | 16.2 |
| Profit before tax | 16.7 | 34.7 | 16.2 |
| Net profit | 11.6 | 28.6 | 11.6 |
| Operating margin | 9.1% | 19.1% | 10.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Net profit, quarter on quarter | -59.40% |
| Revenue, year on year | +11.40% |
BSE results filing, NSE: LINCOLN. Figures extracted from the filing.
Lincoln Pharmaceuticals Ltd: key numbers
- Share price
- ₹564.70
- Market cap
- ₹1,131 Cr
- Revenue (annual)
- ₹671.0 Cr
- Net profit (annual)
- ₹87.89 Cr
- P/E (TTM)
- 11.7×Sector 47.4×
- Promoter holding
- 49.78%+0.00% QoQ
- FII holding
- 4.60%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lincoln Pharmaceuticals Ltd
All →Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.
Lincoln Pharmaceuticals Other Announcement
Lincoln Pharmaceuticals has dispatched physical letters to shareholders with unregistered email IDs to provide access to the Annual Report for FY 2025-26 and facilitate KYC updates.
Lincoln Pharmaceuticals Annual Report
Lincoln Pharmaceuticals submitted its Annual Report for FY 2025-26 and notice for the 32nd Annual General Meeting scheduled for September 30, 2026.
Lincoln Pharmaceuticals Dividend
Lincoln Pharmaceuticals declared a final dividend of ₹1.80 per equity share for FY 2025-26. The 32nd AGM is scheduled for September 30, 2026.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals announced its 32nd AGM for September 30, 2026, and book closure dates from September 12 to 30, 2026, to determine dividend entitlement.
Lincoln Pharmaceuticals Q1 FY27 Results: Net Profit ₹36.2 Cr, Up 30.7% YoY
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹177.3 Cr (+15.1% YoY) and net profit of ₹36.2 Cr (+30.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹36.2 Cr · +30.7% YoY